ACH

Investors need to pay close attention to ACH stock based on the movements in the options market lately.

RICHMOND, Va.--(BUSINESS WIRE)--Accendra Health, Inc. (NYSE: ACH) (the “Company”) today announced the expiration and final results of the previously announced offers to exchange (the “Exchange Offers”) any and all of the Company's outstanding 4.500% Senior Notes due 2029 (the “2029 Notes”) and 6.625% Senior Notes due 2030 (the “2030 Notes” and, together with the 2029 Notes, the “Existing Notes”). As of 5:00 P.M., New York City time, on June 23, 2026 (the “Expiration Time”), the Company received.

RICHMOND, Va.--(BUSINESS WIRE)--Accendra Health, Inc. (NYSE: ACH) (the “Company”) today announced the early results of the previously announced offers to exchange (the “Exchange Offers”) any and all of the Company's outstanding 4.500% Senior Notes due 2029 (the “2029 Notes”) and 6.625% Senior Notes due 2030 (the “2030 Notes” and, together with the 2029 Notes, the “Existing Notes”). Eligible Holders of 2029 Notes that participate in the New Money Notes Issuance (as defined below) will be able to.

RICHMOND, Va.--(BUSINESS WIRE)--Accendra Health, Inc. (NYSE: ACH) (the “Company”) today announced that it has commenced an offer to exchange (the “Exchange Offers”) any and all of the Company's outstanding 4.500% Senior Notes due 2029 (the “2029 Notes”) and 6.625% Senior Notes due 2030 (the “2030 Notes” and, together with the 2029 Notes, the “Existing Notes”). Eligible Holders of 2029 Notes that participate in the New Money Notes Issuance (as defined below) will be able to exchange such 2029 No.

Accendra Health, Inc. (ACH) Shareholder/Analyst Call Prepared Remarks Transcript

Accendra Health, Inc. is undergoing a multiyear turnaround, focusing on at-home medicine after divesting its hospital supply unit and cleaning up its balance sheet. ACH's recent refinancing extends maturities, reduces gross debt by ~$100 million, and provides a liquidity runway, enhancing the probability of successful long-term deleveraging. Management reaffirmed full-year guidance, but ongoing margin pressure and slow volume growth mean EBITDA will likely be at the lower end of the outlook.

Accendra Health, Inc. (ACH) Q1 2026 Earnings Call Transcript

RICHMOND, Va.--(BUSINESS WIRE)--Accendra Health, Inc. (NYSE: ACH) today reported financial results for the first quarter ended March 31, 2026, and announced a more than $1.5 billion comprehensive balance sheet optimization transaction with commitments from existing creditors that will strengthen the balance sheet, significantly extend maturities and reduce total leverage. Unless otherwise noted, the results herein reflect the Company's continuing operations, which represent what was previously.